litlas
Log inCreate account

George Wilding

Active 1985–2024

86
Papers
27,767
Citations
80
h-index
86
i10-index

Citations

Citations per year for George Wilding1931: 1 citations1953: 1 citations1956: 1 citations1986: 1 citations1988: 1 citations1989: 8 citations1990: 11 citations1991: 14 citations1992: 17 citations1993: 21 citations1994: 17 citations1995: 25 citations1996: 27 citations1997: 34 citations1998: 37 citations1999: 71 citations2000: 72 citations2001: 81 citations2002: 99 citations2003: 106 citations2004: 125 citations2005: 125 citations2006: 220 citations2007: 279 citations2008: 237 citations2009: 321 citations2010: 277 citations2011: 326 citations2012: 211 citations2013: 297 citations2014: 250 citations2015: 207 citations2016: 224 citations2017: 196 citations2018: 202 citations2019: 617 citations2020: 580 citations2021: 508 citations2022: 361 citations2023: 289 citations2024: 444 citations2025: 169 citations2026: 3 citations1932–1952: no citations, so these years are not shown1954–1955: no citations, so these years are not shown1957–1985: no citations, so these years are not shown1987: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,118 citing papers, 29.9% of this breakdownUnited Kingdom: 725 citing papers, 7% of this breakdownGermany: 568 citing papers, 5.4% of this breakdownItaly: 532 citing papers, 5.1% of this breakdownFrance: 527 citing papers, 5.1% of this breakdownChina: 522 citing papers, 5% of this breakdownCanada: 519 citing papers, 5% of this breakdownNetherlands: 370 citing papers, 3.6% of this breakdownJapan: 338 citing papers, 3.2% of this breakdownSpain: 315 citing papers, 3% of this breakdownAustralia: 280 citing papers, 2.7% of this breakdownBelgium: 242 citing papers, 2.3% of this breakdown
0%29.9%Other 22.7%

Institutions

Fields

  • Medicine67.8%
  • Biochemistry, Genetics and Molecular Biology22.7%
  • Immunology and Microbiology3.7%
  • Pharmacology, Toxicology and Pharmaceutics1.1%
  • Engineering0.8%
  • Chemistry0.6%
  • Other3.3%

Topics

  • Prostate Cancer Treatment and Research11.2%
  • Prostate Cancer Diagnosis and Treatment6.6%
  • Renal cell carcinoma treatment4.2%
  • Radiopharmaceutical Chemistry and Applications3.3%
  • Cancer Immunotherapy and Biomarkers2.1%
  • Angiogenesis and VEGF in Cancer1.9%
  • Other70.7%

Coauthors

All papers

Open in search
  1. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Authors: Howard I. Scher, Michael J. Morris, Walter M. Stadler, Celestia S. Higano, Ethan Basch, Karim Fizazi, Emmanuel S. Antonarakis, Tomasz M. Beer, Michael A. Carducci, Kim N., Paul G. Corn, Johann S. de Bono, Robert Dreicer, Daniel J. George, Elisabeth I. Heath, Maha Hussain, Wm. Kevin Kelly, Glenn Liu, Christopher J. Logothetis, David M. Nanus, Mark N. Stein, Dana E. Rathkopf, Susan F. Slovin, Charles J. Ryan, Oliver Sartor, Eric J. Small, Matthew Raymond Smith, Cora N. Sternberg, Mary-Ellen Taplin, George Wilding, Peter S. Nelson, Lawrence H. Schwartz, Susan Halabi, Philip W. Kantoff, Andrew J. Armstrong - Journal of Clinical Oncology 2016 cited by 1,603

  2. Therapy-Induced Senescence in Cancer

    Authors: Jonathan A. Ewald, Joshua A. Desotelle, George Wilding, David F. Jarrard - JNCI Journal of the National Cancer Institute 2010 cited by 824

  3. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

    Authors: Howard I. Scher, Susan Halabi, Ian F. Tannock, Michael J. Morris, Cora N. Sternberg, Michael A. Carducci, Mario A. Eisenberger, Celestia S. Higano, Glenn J. Bubley, Robert Dreicer, Daniel Petrylak, Philip W. Kantoff, Ethan Basch, William Kevin Kelly, William D. Figg, Eric J. Small, Tomasz M. Beer, George Wilding, Alison Martin, Maha Hussain - Journal of Clinical Oncology 2008 cited by 2,241

  4. Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

    Authors: Maha Hussain, Catherine M. Tangen, Donna L. Berry, Celestia S. Higano, E. David Crawford, Glenn Liu, George Wilding, Stephen M. Prescott, S.K. Sundaram, Eric J. Small, Nancy A. Dawson, Bryan Donnelly, Peter Venner, Ulka N. Vaishampayan, Paul F. Schellhammer, David I. Quinn, Derek Raghavan, Benjamin Ely, Carol M. Moinpour, Nicholas J. Vogelzang, Ian M. Thompson - New England Journal of Medicine 2013 cited by 568

  5. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Authors: Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Роберто Пили, Georg A. Bjarnason, Xavier García del Muro, Jeffrey A. Sosman, E Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin - Journal of Clinical Oncology 2009 cited by 2,189

  6. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

    Authors: Naomi B. Haas, Judith Manola, Robert G. Uzzo, Keith T. Flaherty, Christopher G. Wood, Christopher J. Kane, Michael A.S. Jewett, Janice P. Dutcher, Michael B. Atkins, Michael Pins, George Wilding, David Cella, Lynne I. Wagner, Surena F. Matin, Timothy M. Kuzel, Wade J. Sexton, Yu-Ning Wong, Toni K. Choueiri, Роберто Пили, Igor Puzanov, Manish Kohli, Walter M. Stadler, Michael A. Carducci, Robert Coomes, Robert S. DiPaola - The Lancet 2016 cited by 638

  7. Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162)

    Authors: Maha Hussain, Catherine M. Tangen, Celestia S. Higano, Paul F. Schelhammer, James R. Faulkner, E. David Crawford, George Wilding, A. Akdaş, Eric J. Small, Bryan Donnelly, Gary R. MacVicar, Derek Raghavan - Journal of Clinical Oncology 2006 cited by 507

  8. Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy

    Authors: Samuel R. Denmeade, Annastasiah Mhaka, Dina Rosen, W. Nathaniel Brennen, Susan L. Dalrymple, Ingrid Dach, Claus Olesen, Bora Gürel, Angelo M. De Marzo, George Wilding, Michael A. Carducci, Craig A. Dionne, Jesper V. Møller, Poul Nissen, S. Brøgger Christensen, John T. Isaacs - Science Translational Medicine 2012 cited by 217

  9. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

    Authors: Shahneen Sandhu, William R. Schelman, George Wilding, Víctor Moreno, Richard D. Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Förster, Aurelius Omlin, N. Kreischer, Khin Thway, Heidrun Gevensleben, Linda Sun, John W. Loughney, Manash Chatterjee, Carlo Toniatti, Christopher L. Carpenter, Robert Iannone, Stan B. Kaye, Johann S. de Bono, Robert M. Wenham - The Lancet Oncology 2013 cited by 558

  10. Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Authors: Robert J. Motzer, Brian I. Rini, Ronald M. Bukowski, Brendan D. Curti, Daniel J. George, Gary R. Hudes, Bruce G. Redman, Kim Margolin, Jaime R. Merchan, George Wilding, Michelle S. Ginsberg, Jennifer Bacik, Sindy T. Kim, Charles M. Baum, M. Dror Michaelson - JAMA 2006 cited by 1,228

  11. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

    Authors: John C. Araujo, Géralyn C. Trudel, Fred Saad, Andrew J. Armstrong, Evan Y. Yu, Joaquim Bellmunt, George Wilding, John McCaffrey, Sérgio Serrano, В. Б. Матвеев, Eleni Efstathiou, Stéphane Oudard, Michael J. Morris, Bruce Sizer, Peter J. Goebell, Axel Heidenreich, Johann S. de Bono, Stephen Begbie, Jun Hyuk Hong, Eduardo Richardet, Enrique Gallardo, Prashni Paliwal, S DURHAM, Shinta Cheng, Christopher J. Logothetis - The Lancet Oncology 2013 cited by 231

  12. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours

    Authors: Devalingam Mahalingam, George Wilding, Samuel R. Denmeade, J. Sarantopoulas, David Cosgrove, Jeremy Cetnar, Nilofer S. Azad, Justine Y. Bruce, Michael R. Kurman, Victoria Allgood, Michael A. Carducci - British Journal of Cancer 2016 cited by 149

  13. Predicting Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy Using a Deep Convolutional Neural Network–Based Artificial Intelligence Tool

    Authors: Savitri Krishnamurthy, Parag Jain, Debu Tripathy, Roland Basset, Ramandeep S. Randhawa, Muhammad Hassan, Wei Huang, Hua Yang, Shivaani Kummar, George Wilding, Rajat Roy - JCO Clinical Cancer Informatics 2023 cited by 24

  14. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

    Authors: Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman, Gary R. Hudes, George Wilding, Robert A. Figlin, Michelle S. Ginsberg, Sindy T. Kim, Charles M. Baum, Samuel E. DePrimo, Jim Z. Li, Carlo L. Bello, Charles P. Theuer, Daniel J. George, Brian I. Rini - Journal of Clinical Oncology 2005 cited by 1,632

  15. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

    Authors: Edward M. Messing, Judith Manola, Jorge L. Yao, Maureen Kiernan, David Crawford, George Wilding, P. Anthony diSant’Agnese, Donald L. Trump - The Lancet Oncology 2006 cited by 905

  16. A Novel Artificial Intelligence–Powered Method for Prediction of Early Recurrence of Prostate Cancer After Prostatectomy and Cancer Drivers

    Authors: Wei Huang, Ramandeep S. Randhawa, Parag Jain, Samuel Hubbard, Jens C. Eickhoff, Shivaani Kummar, George Wilding, Hirak S. Basu, Rajat Roy - JCO Clinical Cancer Informatics 2022 cited by 30

  17. Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer

    Authors: Douglas G. McNeel, Edward J. Dunphy, James G. Davies, Thomas Frye, Laura E. Johnson, Mary Jane Staab, Dorothea Horvath, Jane Straus, Dona Alberti, Rebecca Marnocha, Glenn Liu, Jens C. Eickhoff, George Wilding - Journal of Clinical Oncology 2009 cited by 250

  18. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma

    Authors: Joshua M. Lang, Mahazarin R. Kaikobad, Marianne Wallace, Mary Jane Staab, Dorothea Horvath, George Wilding, Glenn Liu, Jens C. Eickhoff, Douglas G. McNeel, Miroslav Malkovský - Cancer Immunology Immunotherapy 2011 cited by 132

  19. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer

    Authors: Dana E. Rathkopf, Joel Picus, Arif Hussain, Susan Ellard, Kim Nguyen, Thomas Nydam, E. Allen-Freda, Kaushal Mishra, Maria Grazia Porro, Howard I. Scher, George Wilding - Cancer Chemotherapy and Pharmacology 2013 cited by 94

  20. Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

    Authors: Maha Hussain, Bryan Goldman, Cathy Tangen, Celestia S. Higano, Daniel P. Petrylak, George Wilding, A. Akdaş, Eric J. Small, Bryan Donnelly, Subramanian Kanaga Sundram, Patrick A. Burch, Robert S. DiPaola, E. David Crawford - Journal of Clinical Oncology 2009 cited by 216

  21. Prooxidant-Antioxidant Shift Induced by Androgen Treatment of Human Prostate Carcinoma Cells

    Authors: Maureen O. Ripple, George Wilding, William F. Henry, Randall Rago - JNCI Journal of the National Cancer Institute 1997 cited by 311

  22. An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer

    Authors: Glenn Liu, William K. Kelly, George Wilding, Lance Leopold, Kimberli J. Brill, Bradley G. Somer - Clinical Cancer Research 2009 cited by 181

  23. Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

    Authors: Alejandro D. Ricart, Anthony W. Tolcher, Glenn Liu, Kyle D. Holen, Garry Schwartz, Mark R. Albertini, Geoffrey R. Weiss, Salim Yazji, Chee M. Ng, George Wilding - Clinical Cancer Research 2008 cited by 158

  24. Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

    Authors: Douglas G. McNeel, Jens C. Eickhoff, Fred T. Lee, David M. King, Dona Alberti, James P. Thomas, Andreas Friedl, Jill Kolesar, Rebecca Marnocha, Jennifer Volkman, Jianliang Zhang, Luz Hammershaimb, James A. Zwiebel, George Wilding - Clinical Cancer Research 2005 cited by 158